Soliton to Initiate POC Clinical Trials to Treat Fibrotic Scars Using Acoustic
Shockwaves Soliton, Inc., a medical device company with a novel and proprietary platform technology licensed
from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), announced that it is planning a proof
of concept (POC) clinical trial for the use of its RAP technology for the treatment of keloid and hypertrophic scars.... | 
